Local complement inhibition by selective precision-targeted therapies
Current Opinion in Immunology, vol. 98, pp. 102687
Abstract
Excessive complement activation represents a major pathogenic mechanism for a range of serious human diseases. Complement-inhibitory therapeutics have been approved for a number of rare and ultra-rare conditions, with several others in clinical development. The vast majority of these complement-targeted drugs act via systemic inhibition that requires high dosing with associated high cost and, in addition, carries increased risks for developing life-threatening infectious diseases. Local complement inhibition, allowing lower dosing, lower costs, and a better safety profile, therefore, represents an attractive novel strategy. Several approaches to achieve local complement inhibition, including local application and site-specific targeting, are being assessed. This review will primarily focus on the tissue-specific targeting using antibody technologies for approaches both in preclinical and clinical development, and discuss its advantages and limitations. Overall, we see great promise for an upcoming generation of targeted complement inhibitors that enable selective inhibition of complement exclusively at the site of disease.
Authors 5
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands
-
Affiliation as printed
Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
-
Paul W.H.I. Parren Aachen
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands; Gyes BV, Utrecht, the Netherlands
-
Leendert Adrianus Trouw corresponding Aachen Department of Immunology, Leiden University Medical Center
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: L.A.Trouw@LUMC.nl
Cited by 7 stored of 7
7 results
No patents citing this paper on Lens.org (checked 2026-10-11).